Bookmark

Add to MyYahoo RSS

Theravance News

News on Theravance (Ticker: THRX) continually updated from thousands of sources around the net.

Thursday Aug 21 | Freshnews

Theravance Biopharma to Present at Investor Conferences in September 2014

Theravance Biopharma, Inc. announced today that Rick E Winningham, Theravance Biopharma's Chief Executive Officer, is scheduled to present at the following investor conferences in September 2014: Baird 2014 Health Care Conference The New York Palace, New York, New York Thursday, September 4, 2014 2:35 p.m. EDT The presentations will be webcast live ... (more)

Comment?

Related Topix: Startups

Thursday Aug 21 | Seeking Alpha

Theravance Biopharma: Neglected Spinoff Targeting A Huge Underserved Market

Theravance is probably a familiar name to many of you. The pharmaceutical company has received extensive coverage on Seeking Alpha over the years.

Comment?

Related Topix: Startups, Copd, Medicine, Health, Biotech, GlaxoSmithKline, Healthcare Industry

Mon Aug 18, 2014

AmericanBankingNews.com

Theravance (THRX) Announces Quarterly Earnings Results, Beats Estimates By $0.35 EPS

Theravance posted its quarterly earnings results on Monday. The company reported earnings per share for the quarter, beating the consensus estimate of by $0.35, American Banking News.com reports.

Comment?

Related Topix: Startups, Stanley

Sat Aug 16, 2014

AmericanBankingNews.com

Theravance VP Junning Lee Sells 53,424 Shares

Theravance VP Junning Lee unloaded 53,424 shares of Theravance stock on the open market in a transaction that occurred on Wednesday, August 13th.

Comment?

Related Topix: Startups

Thu Aug 14, 2014

AmericanBankingNews.com

Theravance Lowered to Underperform at Robert W. Baird

In other Theravance news, SVP Bradford J. Shafer sold 28,156 shares of the stock in a transaction dated Tuesday, August 12th.

Comment?

Related Topix: Startups, Financial Services, Robert W Baird, Investment Services

Hispanic Business

Theravance Biopharma, Inc. - 10-Q - Management's Discussion and...

This Report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Comment?

Related Topix: Startups, Corporate / Securities Law, Law

Wed Aug 13, 2014

Freshnews

Theravance Biopharma, Inc. Reports Second Quarter 2014 Financial Results

Revenue for the second quarter of 2014 was $3.0 million. Net loss for the second quarter of 2014 was $58.2 million or $1.83 per share.

Comment?

Related Topix: Startups, Health, MRSA

AmericanBankingNews.com

Theravance Sees Significant Drop in Short Interest

Theravance was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totalling 21,928,363 shares, a decline of 7.1% from the July 15th total of 23,592,563 shares, Stock Ratings Network.com reports.

Comment?

Related Topix: Startups

Fri Aug 08, 2014

AmericanBankingNews.com

Theravance Stock Rating Reaffirmed by Zacks

's stock had its "neutral" rating reiterated by Zacks in a research report issued on Friday.

Comment?

Related Topix: Startups

Thu Aug 07, 2014

Hispanic Business

Theravance Inc - 10-Q - Management's Discussion and Analysis of...

The information in this discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended , and Section 21E of the Securities Exchange Act of 1934, as amended.

Comment?

Related Topix: Startups, Corporate / Securities Law, Law

Seeking Alpha

Theravance Reports Increased Patient Access And High Confidence In Dividend

Yesterday, Theravance released its Q2 earnings update. Being still in the early days of its operations, the income statement was of less importance compared to the balance sheet, which was the first without Biopharma .

Comment?

Related Topix: Startups, Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Retail, CVS, CVS Caremark

Wed Aug 06, 2014

Freshnews

Theravance Reports Second Quarter 2014 Financial Results

Royalties earned in the second quarter of 2014 were $3.3 million, which were partially offset by amortization of intangible assets of $2.6 million resulting in net royalty revenues of approximately $0.7 million from Glaxo Group Limited related to net sales of RELVAR /BREO ELLIPTA and ANORO ELLIPTA from GSK.

Comment?

Related Topix: Startups, Food and Drug Administration, Medicine, Asthma, Health, Marketing, CVS Caremark

Sys-Con Media

Theravance, Inc. Appoints Michael W. Aguiar as President and Chief Executive Officer

Mr. Aguiar plans to continue to serve as Theravance's Senior Vice President and Chief Financial Officer until his replacement is identified and appointed.

Comment?

Related Topix: Startups, Biotech, Medicine, Gilead Sciences, Healthcare Industry, UC Irvine, Irvine, CA

Tue Aug 05, 2014

AmericanBankingNews.com

Theravance (THRX) Scheduled to Post Earnings on Wednesday

Theravance is set to release its Q214 earnings data on Wednesday, August 6th. Analysts expect Theravance to post earnings of per share and revenue of $4.39 million for the quarter.

Comment?

Related Topix: Startups, Stanley

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••